

CLINICAL RESEARCH NEWS

OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS		
Research Base	Title	CTSU Activation Date
ECOG-ACRIN	*EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP)	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) <i>Sites must receive approval prior to initiating any study start-up activities.</i>	2/29/2024
NRG	NRG-CC012CD: Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (SYMON) <i>Closed to new practices. Additional sites may be allowed if current sites do not meet requirements. TBD April/May 2025.</i>	5/20/2024
Wake Forest	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/23/2024

* Deemed high priority by the Executive Committee

To meet one of the CCDR grant requirements, Georgia NCORP must open and enroll to at least 3 CCDR studies by July 31, 2025. This accrual goal is reset annually as part of the CCDR grant re-approval process.

This newsletter was generated by:



TOPIC	PAGE
Open CCDR Trials	1
Pending CCDR Trials	2
New Treatment Trials	3
Meetings and Audits	4
Audit Prep Tips	5

CLINICAL RESEARCH NEWS

CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS PENDING ACTIVATION		
Research Base	Title	Description
ALLIANCE	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	<ul style="list-style-type: none"> • 465 Adolescents and young adults (AYAs), 18-39 y/o • Protocol under review • Expected activation: Sept. 2025
	A232402CD: PAGODA Randomized Trial of a Proactive Graduated Dose Adjustment Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	<ul style="list-style-type: none"> • GI cancer patients • Protocol under review • Expected activation: Fall 2025
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors	<ul style="list-style-type: none"> • Recruiting 408 AYAs • Protocol under review • Expected activation: Winter 2025
SWOG	S2417CD: RCT to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance	<ul style="list-style-type: none"> • 650 Stage II or III CRC • Protocol under review • Expected activation: Fall 2025
	S2424CD: Algorithm-enabled Patients Activated in Cancer care through Teams (APACT) to Improve Goals of Care Communication for People with Cancer	<ul style="list-style-type: none"> • Adult cancer patients with planned or active receipt of systemic tx • Protocol under review • Expected start: Winter/Spring 2026
Wake Forest	WF24-09-26CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	<ul style="list-style-type: none"> • Recruiting surgeons who perform abdominopelvic surgery • Expected start: Late Fall 2025

Contact Alaina Newsome (underberga@sjchs.org), GA NCORP CCDR Program Coordinator for questions.

CLINICAL RESEARCH NEWS

RECENTLY ACTIVATED TREATMENT TRIALS; POSTED MARCH-APRIL 2025*		
Research Base	Title	CTSU Activation Date
Canadian Cancer Trials Group (CCTG)	CCTG-BR38: Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer – A Randomized Phase 3 Trial	4/3/2025
Children’s Oncology Group (COG)	ARAR2331: Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)	3/17/2025
	AREN2231: Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)	3/28/2025
Southwest Oncology Group (SWOG)	MM10A-S03: A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy	4/1/2025
	S2414: A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)	3/14/2025

* Please refer to previous newsletters for recently activated Cancer Control and Symptom Management trials.

Congrats **Terri Brannon**, CCRC,
Oncology/Orthopedic Research Nurse
for the Harbin Clinic!

You were the first to answer the
“**Test Your Knowledge**”
quiz correctly!

CLINICAL RESEARCH NEWS

UPCOMING RESEARCH BASE MEETINGS			
Research Base	Date		Location
ECOG	October 22-24, 2025		Philadelphia, PA
NRG	July 24-26, 2025		Washington, DC
SWOG	September 17-20, 2025		Chicago, IL
URCC	September 25-28, 2025		Niagara Falls, NY
Wake Forest	October 6-8, 2025		Asheville, NC
UPCOMING GENERAL MEETINGS			
Organizer	Meeting Title	Date	Location
Georgia NCORP	Administrators, Managers, and Coordinators Meeting	June 5, 2025 3-5pm	Virtual
Georgia Society of Clinical Oncology (GASCO)	GASCO 2025 Annual Meeting & Best of ASCO	August 22-23, 2025	The Hotel at Avalon 9000 Avalon Blvd Alpharetta, GA 30009
UPCOMING ROUTINE AUDITS			
Research Base	Date		Location
ECOG	TBD FOR 2026		TBD
NRG	June 23-27, 2025		Georgia CORE Office 999 Peachtree Street Northeast Atlanta, GA 30309
SWOG	TBD for 2027		TBD
URCC	TBD for 2027		TBD
Wake Forest	TBD for 2027		TBD

* Contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds and audit prep details.

CLINICAL RESEARCH NEWS

AUDIT PREPARATION TIPS

- Conduct ongoing peer-to-peer monitoring
- Close open queries and share trends with team members
- Review internally issued and research base specific Corrective and Preventative Action (CAPA) plans for successful implementation and standardization
- Reconcile pharmacy records/DARFs against subject source and EDC
- Verify PI (or delegated designee) has signed eligibility checklists and AE logs
- Ensure there is an Informed Consent document and discussion for each ICF
- Confirm regulatory binder is current with initial and continuing submissions and approvals, delegation of duty log, training, sponsor memos, note-to-files, etc.
- Do not file internal communication that may be used a “paper trail”.

TEST OF YOUR KNOWLEDGE!

The first person to answer correctly will receive Georgia NCORP swag and a shout-out in the next issue! Send your responses to srichburg@georgiacore.org.

#1: Is a Second Primary cancer metastasized (spread) from the original/initial primary cancer?
Choices: Yes or No

#2: How often is your NCI Registration and Credential Repository (RCR) registration renewed?
Choices: annually, every 2 years, or every 3 years

#3: Who must sign the Short Form?
Choices: The patient and consenting staff (interpreter, PI, etc.), the patient, or the interpreter